Compare BOW & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOW | IRWD |
|---|---|---|
| Founded | 2020 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 734.3M | 663.6M |
| IPO Year | 2024 | 2009 |
| Metric | BOW | IRWD |
|---|---|---|
| Price | $29.86 | $4.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $32.29 | $7.67 |
| AVG Volume (30 Days) | 170.7K | ★ 2.7M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.26 | ★ 1400.00 |
| EPS | ★ 0.48 | 0.24 |
| Revenue | ★ $551,589,000.00 | $298,276,000.00 |
| Revenue This Year | $21.31 | $57.95 |
| Revenue Next Year | $19.15 | $4.39 |
| P/E Ratio | $64.28 | ★ $16.67 |
| Revenue Growth | ★ 29.58 | 8.88 |
| 52 Week Low | $21.21 | $0.72 |
| 52 Week High | $34.21 | $5.78 |
| Indicator | BOW | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 52.12 | 48.25 |
| Support Level | $23.64 | $3.80 |
| Resistance Level | $32.83 | $4.88 |
| Average True Range (ATR) | 1.06 | 0.25 |
| MACD | -0.11 | -0.03 |
| Stochastic Oscillator | 35.84 | 20.55 |
Bowhead Specialty Holdings Inc offers commercial specialty property and casualty insurance products. The company offers underwriting solutions to various businesses across four underwriting divisions, which include Casualty, Professional Liability, Healthcare Liability, and Baleen Specialty. A majority of its revenue is generated from the Casualty division, which specializes in general liability coverage, which protects a company against liability arising from bodily injury, personal injury, or property damage, for risks in the construction, distribution, heavy manufacturing, real estate, public entity, and hospitality segments, and also considers underwriting risks in a broader range of industries. Geographically, the company operates in the United States.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.